Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral OKT3 in active ulcerative colitis
NCT01287195Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2011
- Primary completion
- May 2013
- Countries
- 1
01
Overview
A Phase 2 trial of muromonab-CD3 in ulcerative colitis (UC), sponsored by Brigham and Women's Hospital. Started Apr 2011; status: completed.
02
Drugs
muromonab-CD3
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01287195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287195.